耐醇的Aspergillus fumigatus:你需要知道的
Shawn R Lockhart1, Karlyn Beer1, Mitsuru Toda1
1Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA.
Clinical microbiology newsletter
|April 3, 2025
概括
由于特定的基因突变,Aspergillus fumigatus中的醇耐药性正在增加. 抗真菌敏感性测试对于在临床环境中识别这种耐药性至关重要.
科学领域:
- 菌类学 菌类学是指菌类学.
- 传染性疾病 传染性疾病
- 抗微生物耐药性 抗微生物耐药性
背景情况:
- 阿斯伯吉洛症是一种常见的真菌感染,主要是由Aspergillus fumigatus引起的.
- 越来越多的报告表明,A. fumigatus分离体对醇抗真菌药物有耐药性.
- 这种耐药性在治疗真菌感染方面构成了重大挑战.
研究的目的:
- 审查耐醇的A. fumigatus的原因和影响.
- 讨论抗真菌敏感性测试在识别醇耐药性的作用.
主要方法:
- 对A. fumigatus中醇耐药性的研究进行文献综述.
- 分析常见的耐药性机制,包括CYP51A突变 (TR34/L98H,TR46/Y121F/T289A).
主要成果:
- 环境中获得的CYP51A基因突变是对醇耐药性的主要原因.
- 美国有限的抗真菌敏感性测试能力阻碍了对耐药性程度的理解.
- 醇耐药性对阿斯伯吉洛症治疗有着重要的临床影响.
结论:
- 耐醇的A. fumigatus是一种新兴的威胁.
- 抗真菌敏感性测试对于临床管理和监测至关重要.
- 需要进一步努力来扩大测试能力和解决耐药性.
相关概念视频
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Pulmonary Tuberculosis V
157
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
157
Drugs for Treatment of Diarrhea-Predominant IBS
126
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
126
Antiasthma Drugs: Leukotriene Modifiers
180
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
180
Carrier-Mediated Transport
223
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
223
Drug-Receptor Interaction: Antagonist
2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K


